Gilead Sciences
The iMMagine-1 data suggest anito-cel could have a differentiated safety and efficacy profile compared to available BCMA-directed therapies.
Israeli Oncologists Show Point-of-Care CAR T Cells Have Comparable Efficacy to Yescarta, Kymriah
Premium
Lymphoma patients better tolerated the CAR T-cell therapy manufactured on-site at the Sheba Medical Center than they did the commercially available options.
Gilead Sciences to Lay Off 72 Employees, Shutter Seattle Office
The cuts, which will go into effect mid-January, come a year after the drugmaker slashed 7 percent of the workforce at Kite Pharma, its cell therapy business.
Arcus Confident in Anti-TIGIT, Immunotherapy, Chemo Regimen After Seeing Phase II Survival Data
Premium
The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.
Gilead has high hopes that anito-cel, a multiple myeloma cell therapy it is developing with Arcellx, can bolster its cell therapy franchise.